A window on today's China for Southeast Asia
A full century has passed since the Communist Party of China (CPC) was founded in 1921. After 100 years of vigorous growth, the CPC has become the world’s biggest ruling party that has governed the world’s largest socialist country for more than 70 years and owns more than 91 million members. The CPC has led the Chinese nation to make a great leap from standing up to growing rich and becoming strong, creating a “Miracle of the East” that has attracted worldwide attention.
On the morning of July 1, 2021, a ceremony marking the centenary of the Communist Party of China (CPC) was held in Tian’anmen Square in Beijing. Xi Jinping, general secretary of the CPC Central Committee, Chinese president, and chairman of the Central Military Commission, delivered an important speech at the ceremony. People from all walks of life in ASEAN countries have extended warm congratulations on the 100th anniversary of the founding of the CPC.
Good neighbors, good friends, good comrades, and good partners for 60 years, the two countries are now building a closer community with a shared future
Two days ago, I announced that China would provide Cambodia with 1 million doses of COVID-19 vaccines,” wrote Cambodian Prime Minister Samdech Techo Hun Sen in a January 17 Facebook post. “To boost confidence in the vaccine, I declare that I will be the first to be vaccinated in Cambodia. I must be at the forefront of this campaign.”
The office building of Beijing Institute of Biological Products Co., Ltd. (BJIBP) under China National Biotec Group (CNBG) in Beijing’s southeastern outskirts was still brightly lit at 9:00 p.m. on December 25, 2020. Dong Jianchun, head of engineering support, his deputy Shi Wei, and technical team leader Zhang Yu were feverishly pouring over a design plan for the company’s second production facility for the inactivated COVID-19 vaccine. They were checking implementation details related to the project as construction work entered the final stage and testing of production equipment was about to commence.
On a hot morning in July 2020, Liang Hongyang, deputy director of the No. 6 Vaccine Office of the Beijing Institute of Biological Products (BJIBP) under China National Biotec Group (CNBG), a subsidiary of China National Pharmaceutical Group (Sinopharm), rushed into the lab working on the COVID-19 vaccine. When he left the BJIBP building, Liang saw tents were pitched and people were waiting in a long queue to get vaccinated. He overheard someone say, “I finally feel safe after getting vaccinated.”
China Report ASEAN 